AirWare Labs Files New Patent Application for Oxygen Therapy

Life Science Investing News

AirWare Labs Corp. (OTCQB:AIRW) filed a new patent application for an oxygen cannula delivery system. The delivery system will feature a proprietary cannula design, fitted with disposable nasal dilators that diffuse the stream of oxygen as it enters the nasal passage and prevent nasal dryness.

AirWare Labs Corp. (OTCQB:AIRW) filed a new patent application for an oxygen cannula delivery system. The delivery system will feature a proprietary cannula design, fitted with disposable nasal dilators that diffuse the stream of oxygen as it enters the nasal passage and prevent nasal dryness.

As quoted in the press release:

The nasal dilators also work to open the nasal passage and increase airflow by up to 60%, enhancing the overall effectiveness of oxygen therapy.

Click here to read the AirWare Labs Corp. (OTCQB:AIRW) press release

See this press release on Marketwire

The Conversation (0)
×